Trial
NCT05243641
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Celcuity Inc; Novartis; Puma Biotechnology, Inc.
Condition
Metastatic Breast Cancer
Intervention
Neratinib
Why stopped
Sponsor Withdrew Support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-11